TY - JOUR
T1 - Porin-independent accumulation in Pseudomonas enables antibiotic discovery
AU - Geddes, Emily J.
AU - Gugger, Morgan
AU - Garcia, Alfredo
AU - Garcia Chavez, Martin
AU - Lee, Myung Ryul
AU - Perlmutter, Sarah J.
AU - Bieniossek, Christoph
AU - Guasch, Laura
AU - Hergenrother, Paul
N1 - We thank the NIH (AI136773), the University of Illinois and Roche for support of this work. M.K.G. is a member of the NIH Chemistry-Biology Interface Training Grant (T32-GM136629). We thank L. Li (Metabolomics Center, Roy J. Carver Biotechnology Center, UIUC and Duke University School of Medicine Proteomics and Metabolomics Core Facility) for all LC–MS/MS analysis. We thank D. Olson, L. Zhu and N. Duay at the School of Chemical Sciences NMR Laboratory at UIUC for NMR services. We thank A. Cyphersmith and the Core Facilities at the Carl Woese Institute for Genomic Biology for assistance with confocal imaging. We are grateful to all past Hergenrother laboratory members who have contributed compounds to the complexity-to-diversity collection and to B. Drown, who wrote the code used for the random forest analysis. We thank H. Zgurskaya for the generous donation of the P. aeruginosa PA01 Δ6 and PA01 Δ6-pore strains and D. Bumann for the generous donation of the P. aeruginosa PA14 and PA14 Δ40 strain. We are further grateful to collaborators at Roche, including C. Kramer who helped establish this collaboration early on and G. M. Daniel for his guidance of the collaboration as alliance manager.
We thank the NIH (AI136773), the University of Illinois and Roche for support of this work. M.K.G. is a member of the NIH Chemistry-Biology Interface Training Grant (T32-GM136629). We thank L. Li (Metabolomics Center, Roy J. Carver Biotechnology Center, UIUC and Duke University School of Medicine Proteomics and Metabolomics Core Facility) for all LC–MS/MS analysis. We thank D. Olson, L. Zhu and N. Duay at the School of Chemical Sciences NMR Laboratory at UIUC for NMR services. We thank A. Cyphersmith and the Core Facilities at the Carl Woese Institute for Genomic Biology for assistance with confocal imaging. We are grateful to all past Hergenrother laboratory members who have contributed compounds to the complexity-to-diversity collection and to B. Drown, who wrote the code used for the random forest analysis. We thank H. Zgurskaya for the generous donation of the P. aeruginosa PA01 Δ6 and PA01 Δ6-pore strains and D. Bumann for the generous donation of the P. aeruginosa PA14 and PA14 Δ40 strain. We are further grateful to collaborators at Roche, including C. Kramer who helped establish this collaboration early on and G. M. Daniel for his guidance of the collaboration as alliance manager.
PY - 2023/12/7
Y1 - 2023/12/7
N2 - Gram-negative antibiotic development has been hindered by a poor understanding of the types of compounds that can accumulate within these bacteria1,2. The presence of efflux pumps and substrate-specific outer-membrane porins in Pseudomonas aeruginosa renders this pathogen particularly challenging3. As a result, there are few antibiotic options for P. aeruginosa infections4 and its many porins have made the prospect of discovering general accumulation guidelines seem unlikely5. Here we assess the whole-cell accumulation of 345 diverse compounds in P. aeruginosa and Escherichia coli. Although certain positively charged compounds permeate both bacterial species, P. aeruginosa is more restrictive compared to E. coli. Computational analysis identified distinct physicochemical properties of small molecules that specifically correlate with P. aeruginosa accumulation, such as formal charge, positive polar surface area and hydrogen bond donor surface area. Mode of uptake studies revealed that most small molecules permeate P. aeruginosa using a porin-independent pathway, thus enabling discovery of general P. aeruginosa accumulation trends with important implications for future antibiotic development. Retrospective antibiotic examples confirmed these trends and these discoveries were then applied to expand the spectrum of activity of a gram-positive-only antibiotic, fusidic acid, into a version that demonstrates a dramatic improvement in antibacterial activity against P. aeruginosa. We anticipate that these discoveries will facilitate the design and development of high-permeating antipseudomonals.
AB - Gram-negative antibiotic development has been hindered by a poor understanding of the types of compounds that can accumulate within these bacteria1,2. The presence of efflux pumps and substrate-specific outer-membrane porins in Pseudomonas aeruginosa renders this pathogen particularly challenging3. As a result, there are few antibiotic options for P. aeruginosa infections4 and its many porins have made the prospect of discovering general accumulation guidelines seem unlikely5. Here we assess the whole-cell accumulation of 345 diverse compounds in P. aeruginosa and Escherichia coli. Although certain positively charged compounds permeate both bacterial species, P. aeruginosa is more restrictive compared to E. coli. Computational analysis identified distinct physicochemical properties of small molecules that specifically correlate with P. aeruginosa accumulation, such as formal charge, positive polar surface area and hydrogen bond donor surface area. Mode of uptake studies revealed that most small molecules permeate P. aeruginosa using a porin-independent pathway, thus enabling discovery of general P. aeruginosa accumulation trends with important implications for future antibiotic development. Retrospective antibiotic examples confirmed these trends and these discoveries were then applied to expand the spectrum of activity of a gram-positive-only antibiotic, fusidic acid, into a version that demonstrates a dramatic improvement in antibacterial activity against P. aeruginosa. We anticipate that these discoveries will facilitate the design and development of high-permeating antipseudomonals.
UR - http://www.scopus.com/inward/record.url?scp=85177586710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85177586710&partnerID=8YFLogxK
U2 - 10.1038/s41586-023-06760-8
DO - 10.1038/s41586-023-06760-8
M3 - Article
C2 - 37993720
SN - 0028-0836
VL - 624
SP - 145
EP - 153
JO - Nature
JF - Nature
IS - 7990
ER -